Diabetes and Decline in Heart Disease Mortality in US Adults JAMA. 1999;281:

Similar documents
Over the past several decades, mortality from cardiovascular

This chapter examines the sociodemographic

YOUNG ADULT MEN AND MIDDLEaged

Hypertension is an important factor in premature death,

Diabetes Incidence in Rochester, Minnesota Burke et al. Impact of Case Ascertainment on Recent Trends in Diabetes Incidence in Rochester, Minnesota

Antihypertensive Drug Therapy and Survival by Treatment Status in a National Survey

An Explanation for the Increase in Heart Disease Mortality Rates in Diabetic Pima Indians

Temporal Trends in Prevalence of Diabetes Mellitus in a Population-Based Cohort of Incident Myocardial Infarction and Impact of Diabetes on Survival

A Population'based Study of

ORIGINAL INVESTIGATION. Diabetes Mellitus and Nontraumatic Lower Extremity Amputation in Black and White Americans

Elevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes

POOR LONG-TERM SURVIVAL AFTER ACUTE MYOCARDIAL INFARCTION AMONG PATIENTS ON LONG-TERM DIALYSIS

The New England Journal of Medicine

Determinants of the decline in mortality attributable

Supplementary Appendix

Based on the National Hospital Discharge Survey

Relative Contributions of Incidence and Survival to Increasing Prevalence of Adult-Onset Diabetes Mellitus: A Population-based Study

The Impact of Diabetes Mellitus and Prior Myocardial Infarction on Mortality From All Causes and From Coronary Heart Disease in Men

Age and the Burden of Death Attributable to Diabetes in the United States

Lifetime Risk of Cardiovascular Disease Among Individuals with and without Diabetes Stratified by Obesity Status in The Framingham Heart Study

Trends in the Incidence of Type 2 Diabetes Mellitus From the 1970s to the 1990s The Framingham Heart Study

Changes in Incidence of Diabetes in U.S. Adults,

Improving the comparability of diabetes mortality statistics in the United States and Mexico

THE CURRENT INCREASE IN OBEsity

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups

ARIC Manuscript Proposal #1233. PC Reviewed: 4_/_10/07 Status: _A Priority: 2_ SC Reviewed: Status: Priority:

Secular Trends in Birth Weight, BMI, and Diabetes in the Offspring of Diabetic Mothers

Application of New Cholesterol Guidelines to a Population-Based Sample

Application of New Cholesterol Guidelines to a Population-Based Sample

ARIC Manuscript Proposal # PC Reviewed: 05/12/09 Status: A Priority: 2 SC Reviewed: Status: Priority:

Current Use of Unopposed Estrogen and Estrogen Plus Progestin and the Risk of Acute Myocardial Infarction Among Women With Diabetes

Age-adjusted mortality from coronary heart disease (CHD)

EFFECT OF BODY MASS INDEX ON LIFETIME RISK FOR DIABETES MELLITUS IN THE UNITED STATES

Diabetes. Health Care Disparities: Medical Evidence. A Constellation of Complications. Every 24 hours.

IMPACT OF RECENT CHANGES IN DIAGNOSTIC CRITERIA ON THE APPARENT NATURAL HISTORY OF DIABETES MELLITUS

Coronary Atherosclerosis in Diabetes Mellitus A Population-Based Autopsy Study

Glucose tolerance and mortality, including a substudy of tolbutamide treatment

Prediction of Cardiovascular Death in Racial/Ethnic Minorities Using Framingham Risk Factors

CONSIDERABLE STRIDES HAVE

Diabetes and All-Cause and Coronary Heart Disease Mortality Among US Male Physicians

I t is well established that non-insulin dependent diabetes is

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG

ARIC Manuscript Proposal # PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority:

RATES of mortality from coronary heart disease

The New England Journal of Medicine TRENDS IN THE INCIDENCE OF CORONARY HEART DISEASE AND CHANGES IN DIET AND LIFESTYLE IN WOMEN

Mortality following acute myocardial infarction (AMI) in

Reliability of Reported Age at Menopause

ARTICLE. A. Icks & T. Dickhaus & A. Hörmann & M. Heier & G. Giani & B. Kuch & C. Meisinger

ORIGINAL INVESTIGATION. Risk Factors for Congestive Heart Failure in US Men and Women

Diabetes Care 25: , 2002

National public health campaigns have attempted

ORIGINAL INVESTIGATION. Effects of Prehypertension on Admissions and Deaths

Statistical Fact Sheet Populations

The Whitehall II study originally comprised 10,308 (3413 women) individuals who, at

Serum uric acid levels improve prediction of incident Type 2 Diabetes in individuals with impaired fasting glucose: The Rancho Bernardo Study

Projection of Diabetes Burden Through 2050

ORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults

Serum Uric Acid and Cardiovascular Mortality

The Best Lipid Fraction for the Prediction of the Population at Risk of Atherothrombotic Disease. William E. Feeman, Jr., M.D.

Improving the Comparability of Diabetes Mortality Statistics in the U.S. and Mexico

ORIGINAL INVESTIGATION. The Impact of Diabetes Mellitus on Mortality From All Causes and Coronary Heart Disease in Women

Cardiovascular Disease Risk of Abdominal Obesity vs. Metabolic Abnormalities

The Prognostic Importance of Comorbidity for Mortality in Patients With Stable Coronary Artery Disease

Hemoglobin A1C and diabetes diagnosis: The Rancho Bernardo Study

Supplementary Appendix

Diabetes Duration and Cause-Specific Mortality in the Verona Diabetes Study

Impaired glucose tolerance as a risk factor for stroke in a cohort of non-institutionalised people aged 70 years

From Policemen to Policies: What Is the Future for 2-h Glucose?

DATA FROM THE THIRD NAtional

Trends in Blood Pressure, Hypertension Control, and Stroke Mortality: The Minnesota Heart Survey

ORIGINAL INVESTIGATION. Risk Factors for Coronary Heart Disease in African Americans. The Atherosclerosis Risk in Communities Study,

Transfer in D2B. Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland. The Problem

ORIGINAL INVESTIGATION. Fasting and 2-Hour Postchallenge Serum Glucose Measures and Risk of Incident Cardiovascular Events in the Elderly

United States General Accounting Office. Testimony Before the Select Committee on Aging, House of Representatives

10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice

Supplementary Online Content

Statins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review.

Cedars Sinai Diabetes. Michael A. Weber

Blood Pressure Usually Considered Normal Is Associated with an Elevated Risk of Cardiovascular Disease

J Am Soc Nephrol 14: , 2003

Diabetologia 9 Springer-Verlag 1991

FOR MIDDLE-AGED POPULATIONS,

Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution

It is well established that type 2 diabetes (non insulindependent. Nonfasting Serum Glucose and Insulin Concentrations and the Risk of Stroke

Journal of the American College of Cardiology Vol. 50, No. 11, by the American College of Cardiology Foundation ISSN /07/$32.

Relative Impact of Targeted Versus Populationwide Cholesterol Interventions

Association between metabolic risk factors and cardiovascular disease mortality: population-level analysis in high income countries

THE PREVALENCE OF OVERweight

Cardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes

Plasma lipids can be reliably assessed within 24 hours after

Although the prevalence and incidence of type 2 diabetes mellitus

HIGH BLOOD PRESSURE IS AN EStablished

THE HEALTH consequences of

Primary prevention of Cardiovascular Diseases: Differences between European and United States Guidelines

ARIC Manuscript Proposal # PC Reviewed: _12/20/05 Status: Priority: SC Reviewed: Status: Priority:

Non-fasting lipids and risk of cardiovascular disease in patients with diabetes mellitus

TEN-YEAR ABSOLUTE RISK ESTImates

Plasma Glucose and Prediction of Microvascular Disease and Mortality

Transcription:

ORIGINAL CONTRIBUTION and Decline in Mortality in US Adults Ken Gu, PhD Catherine C. Cowie, PhD, MPH Maureen I. Harris, PhD, MPH MORTALITY FROM HEART disease has declined substantially in the United States during the past 3 years. 1-4 Because heart disease is the major cause of death associated with diabetes, 5,6 it would be expected that the mortality decline in the United States as a whole also would have been experienced by those with diabetes. However, no study has examined whether people with diabetes in the United States have benefited from this general phenomenon and, if so, whether the extent of their mortality rate decline is similar to that of people without diabetes. To examine these issues, we analyzed mortality in 2 representative national cohorts derived from subjects in the First National Health and Nutrition Examination Survey (NHANES I) of 1971 through 1975 and the NHANES I Epidemiologic Follow-up Survey (NHEFS) of 1982 through 1984. Both cohorts were followed up prospectively for mortality for an average of 8 to 9 years. METHODS NHANES I included a national probability sample of 14 376 persons aged 25 to 74 years who were interviewed for sociodemographic information and history of diabetes. The NHANES I subjects were followed up in 1982-1984, 1986, 1987, and 1992-1993 in the NHEFS. In each follow-up, the subjects (or their proxies) were interviewed again to determine vital status Context Mortality from coronary heart disease has declined substantially in the United States during the past 3 years. However, it is unknown whether patients with diabetes have also experienced a decline in heart disease mortality. Objective To compare adults with diabetes with those without diabetes for time trends in mortality from all causes, heart disease, and ischemic heart disease. Design, Setting, and Participants Representative cohorts of subjects with and without diabetes were derived from the First National Health and Nutrition Examination Survey (NHANES I) conducted between 1971 and 1975 (n = 9639) and the NHANES I Epidemiologic Follow-up Survey conducted between 1982 and 1984 (n = 8463). The cohorts were followed up prospectively for mortality for an average of 8 to 9 years. Main Outcome Measure Changes in mortality rates per 1 person-years for all causes, heart disease, and ischemic heart disease for the 1982-1984 cohort compared with the 1971-1975 cohort. Results For the 2 periods, nondiabetic men experienced a 36.4% decline in ageadjusted heart disease mortality compared with a 13.1% decline for diabetic men. Ageadjusted heart disease mortality declined 27% in nondiabetic women but increased 23% in diabetic women. These patterns were also found for all-cause mortality and ischemic heart disease mortality. Conclusions The decline in heart disease mortality in the general US population has been attributed to reduction in cardiovascular risk factors and improvement in treatment of heart disease. The smaller declines in mortality for diabetic subjects in the present study indicate that these changes may have been less effective for people with diabetes, particularly women. JAMA. 1999;281:1291-1297 www.jama.com (alive or dead), whether diabetes had been diagnosed, and other information. Follow-up was completed for 96% of subjects. 5 Two nationally representative cross-sectional samples of adults aged 35 to 74 years were created from these data. Cohort 1 was derived from 1 649 people in NHANES I who were aged 35 to 74 years at the time of their 1971-1975 interview. Cohort 2 was derived from 9233 subjects in NHEFS who were aged 35 to 74 years on the date of the self or proxy interview in 1982-1984. Cohort 1 Of the 1 649 subjects aged 35 to 74 years in NHANES I, 67 subjects (285 men and 385 women) reported a physician diagnosis of diabetes and were defined as having diabetes. It has previously been demonstrated that a selfreport of physician-diagnosed diabetes is accurate and valid. 7-9 Of the 9979 subjects without a history of diabetes, 111 individuals were excluded from analysis, including 17 subjects for whom any follow-up interview data indicated that they had been diagnosed as having diabetes and 4 subjects who had diabetes listed on their death cer- Author Affiliations: National Institute of and Digestive and Kidney s, Bethesda, Md. Corresponding Author and Reprints: Maureen I. Harris, PhD, MPH, National Institute of and Digestive and Kidney s, National Institutes of Health, Natcher Bldg, Room 5AN24, 45 Center Dr, MSC 66, Bethesda, MD 892 (e-mail: harrism@ep.niddk.nih.gov). 1999 American Medical Association. All rights reserved. JAMA, April 14, 1999 Vol 281, No. 14 1291 Downloaded From: on 11/14/18

tificate. The remaining 8869 subjects (3826 men and 543 women) were defined as not having diabetes. The follow-up period for cohort 1 was from the date of the 1971-1975 interview to the date of the self or proxy interview in 1982-1984. The mean follow-up was 9.1 years, during which time there were 264 deaths among subjects with diabetes and 1625 deaths among subjects without diabetes. Cohort 2 Of the 9233 subjects in NHEFS who were aged 35 to 74 years on the date of the self or proxy interview in 1982-1984, there were 637 subjects (233 men and 44 women) with diabetes. This included 271 who had diabetes in the 1971-1975 survey and 366 who did not have diabetes in 1971-1975 but stated in the 1982-1984 interview that they had been diagnosed as having diabetes. Of the remaining 8596 subjects, 77 were excluded from analysis, including 435 subjects who had a diagnosis of diabetes made after the 1982-1984 interview, 1 subjects without diabetes in 1982-1984 who died and had diabetes listed as a cause of death on their death certificate, and 325 subjects with unknown diabetes status. The remaining 7826 subjects (2841 men and 4985 women) were defined as not having diabetes. The follow-up period for cohort 2 was from the date of the 1982-1984 interview to the date of death or the date of the last follow-up interview. The mean follow-up was 8.7 years, during which time there were 184 deaths among subjects with diabetes and 747 deaths among those without diabetes. Although all cohort 1 and cohort 2 members were part of the NHANES I survey, there was only a 3% to 8% overlap in the 1-year age and diabetes groups used in analysis. The lack of overlap occurred because the beginnings of the cohort observation periods were an average of 9.7 years apart and, thus, most subjects aged 65 to 74 years in cohort 1 were not in cohort 2, most subjects aged 35 to 44 years in cohort 2 were not in cohort 1, and most subjects aged 35 to 64 years in cohort 1 were in an older 1-year age group in cohort 2. In addition, 366 subjects had diabetes in cohort 2 but not in cohort 1. The type of diabetes in this study could not be determined, but the adult Figure 1. Age-Specific Mortality Rates for Death Due to,, and for and With and Without in Cohorts 1 and 2, According to Age at Baseline Rate per 1 1 1 8 6 4 6 5 4 3 1 5 4 3 1 Rate per 1 8 7 6 5 4 3 1 45 4 35 3 25 15 1 5 35-54 55-64 65-74 35-54 55-64 65-74 35-54 55-64 65-74 35-54 55-64 65-74 35-54 55-64 65-74 35-54 55-64 65-74 Age Range, y 35 3 25 15 1 5 Mortality rates are shown per 1 person-years with 95% confidence intervals. Cohort 1 was defined in 1971-1975 and was followed up for mortality through 1982-1984. Cohort 2 was defined in 1982-1984 and was followed up for mortality through 1992-1993. Details about sample sizes, number of deaths, point estimates, and statistical significance are shown in Tables 1 and 2. 1292 JAMA, April 14, 1999 Vol 281, No. 14 1999 American Medical Association. All rights reserved. Downloaded From: on 11/14/18

age of the cohorts and the high proportion of type 2 diabetes in the US population with diabetes 1,11 indicate that the cohorts contained type 2 diabetes almost exclusively. Death due to any heart disease or ischemic heart disease was based on the underlying cause of death on the death certificates, which were coded using the International Classification of s, Ninth Revision. Codes used for heart disease were 39-398, 42, 44, 41-417, and 4-429, and for ischemic heart disease, 41-414. Death certificates were obtained for 97.3% of decedents who had had diabetes and 96.5% of decedents who had not had diabetes. Statistical Analyses Age-specific mortality rates per 1 person-years were calculated using the number of deaths as the numerator and total years of follow-up as the denominator for 3 age groups (35-54, 55-64, and 65-74 years) stratified by cohort, diabetes status, and sex. The variance of the personyear rate was estimated by the Chiang method. 12,13 Age-adjusted mortality rates for each cohort stratified by diabetes status and sex were calculated by the direct method, using four 1-year age groups (35-44, 45-54, 55-64, and 65-74 years) and the 198 US population as the standard. The variance of the ageadjusted rate was calculated by summing the variance of each age-specific rate multiplied by the square of its US population proportion. The percentage difference between cohort 1 and cohort 2 was calculated as the mortality rate in cohort 2 minus the rate in cohort 1, divided by the rate in cohort 1, and multiplied by 1. The variance of the percentage difference was estimated by a Taylor series approximation for estimation of the variance of a ratio from a sample. 14 Variance of the relative risk was computed by the same method. Covarianceduetothesmalloverlapbetweencohort1andcohort2wasnotconsidered in computing variance estimates because the overlap was only 3% to 8% in the 1-year age and diabetes groups used in analysis, as explained herein. The cohorts were divided into deciles of age for examination of mean age; there were no significant differences in mean age by sex and diabetes status in any of the age groups. The race distribution differed nonsignificantly between the 2 cohorts; nonwhites constituted 19.1% of cohort 1 and 18.9% of cohort 2. RESULTS FIGURE 1 shows mortality from all causes, heart disease, and ischemic heart disease for men and women with and without diabetes in cohort 1 and cohort 2, according to age at baseline. Details about sample sizes; person-years of follow-up; number of deaths by age, sex, and diabetes status; and statistical Table 1. All-Cause Mortality Rates for Adults in Cohorts 1 and 2, by Status, Sex, and Age* Subjects Person- Years of Follow-up Rate per 1 Subjects Person- Years of Follow-up Rate Per 1 Change From Cohort 1 to Cohort 2, % Age, y 35-54 66 611.5 1 16.4 (7.8-24.9) 67 546.8 1 18.3 (8.9-27.7) 11.8.76 55-64 48 365.1 23 63. (44.4-81.6) 83 617.8 29 46.9 (33.5-6.4) 25.5.17 65-74 171 11.6 111 92.4 (82.-12.8) 83 53.9 53 99.8 (84.3-115.4) 8.1.44 35-74 (Age 285 2178.1 144 4.7 (33.4-48.) 233 1695.5 92 4.2 (32.2-48.1) 1.2.93 35-54 1667 15 674.4 152 9.7 (8.3-11.1) 1586 14 68.9 79 5.6 (4.4-6.8) 42.1.1 55-64 687 5969.8 151 25.3 (21.7-28.8) 734 6262.9 118 18.8 (15.7-21.9) 25.5.7 65-74 1472 11 639.3 695 59.7 (56.4-63.) 521 392.7 9 53.6 (48.-59.1) 1.3.6 35-74 (Age 3826 33 283.5 998 22.4 (21.1-23.8) 2841 24 234.4 46 17.6 (16.2-19.1) 21.4.1 35-54 12 979.3 9 9.2 (3.7-14.7) 198 1662.7 21 12.6 (7.9-17.4) 37.4.35 55-64 74 677.7 18 26.6 (15.8-37.3) 13 832.7 27 32.4 (22.-42.8) 22.1.44 65-74 9 1681.5 93 55.3 (46.8-63.8) 13 743.1 44 59.2 (46.3-72.1) 7.1.62 35-74 (Age 385 3338.5 1 21.6 (17.3-25.9) 44 3238.6 92 24.9 (.6-29.2) 15.2.29 35-54 27 26 743.8 15 3.9 (3.2-4.6) 3348 3 162.1 1 3.3 (2.7-3.9) 15.6.21 55-64 768 7173.7 77 1.7 (8.5-13.) 969 8577.9 94 11. (8.9-13.1) 2.1.89 65-74 1555 13 98.7 445 31.8 (29.3-34.3) 668 5544.5 147 26.5 (22.8-3.3) 16.7.2 35-74 (Age 543 47 898.2 627 1.8 (9.9-11.6) 4985 44 284.6 341 9.4 (8.5-1.3) 12.6.4 *CI indicates confidence interval. 1999 American Medical Association. All rights reserved. JAMA, April 14, 1999 Vol 281, No. 14 1293 P Value Downloaded From: on 11/14/18

significance are provided in TABLE 1 and TABLE 2. For all groups, mortality rates increased with age, were higher in men than women, and were higher in subjects with diabetes than their counterparts without diabetes. Among men and women without diabetes, mortality rates were higher in cohort 1 than cohort 2 for almost all age groups and causes of death. The differences between cohort 1 and cohort 2 were statistically significant for men without Table 2. Mortality Rates for and as the Underlying Cause for Adults in Cohorts 1 and 2, by Status, Sex, and Age* Rate per 1 Rate per 1 Change from Cohort 1 to Cohort 2, % Age at Baseline, y 35-54 6 9.8 (2.7-16.9) 3 5.5 (.-11.4) 44.1.36 55-64 11 3.1 (14.8-45.4) 14 22.7 (12.1-33.4) 24.5.44 65-74 53 45.1 (35.4-54.7) 26 49. (34.3-63.6) 8.6.67 35-74 (Age 7.4 (14.6-26.3) 43 17.8 (12.3-23.2) 13.1.51 35-54 65 4.1 (3.2-5.1) 28 2. (1.3-2.7) 52..1 55-64 6 1.1 (7.7-12.5) 32 5.1 (3.4-6.8) 49.3.1 65-74 288 24.9 (22.4-27.4) 75 19.3 (15.4-23.3) 22.4.2 35-74 (Age 413 9.3 (8.4-1.2) 135 5.9 (5.-6.8) 36.4.1 35-54 5 5.1 (.9-9.4) 11 6.7 (3.-1.4) 3.9.58 55-64 8 11.8 (4.1-19.5) 1 12. (5.-19.) 1.7.97 65-74 38 22.7 (16.3-29.2) 23 31.6 (.6-42.6) 39..17 35-74 (Age 51 9.8 (6.6-13.) 44 12. (8.7-15.3) 22.9.34 35-54 24.9 (.5-1.3) 15.5 (.3-.7) 44.6.7 55-64 24 3.4 (2.-4.7) 23 2.7 (1.6-3.8)..44 65-74 17 12.2 (1.5-14.) 51 9.2 (6.8-11.7) 24.5.5 35-74 (Age 218 3.6 (3.1-4.1) 89 2.6 (2.1-3.2) 27.1.9 35-54 5 8.2 (1.6-14.8) 2 3.7 ( 1.2-8.5) 55.3.28 55-64 9 24.7 (1.4-38.9) 12 19.5 (9.5-29.5).9.56 65-74 44 37.4 (28.3-46.6) 37.7 (24.-51.3).6.98 35-74 (Age 58 17. (11.5-22.6) 34 14.2 (9.1-19.4) 16.6.46 35-54 53 3.4 (2.5-4.3) 22 1.6 (.9-2.2) 53.8.1 55-64 48 8.1 (5.9-1.3) 21 3.4 (1.9-4.8) 58.4.1 65-74 226 19.5 (17.2-21.8) 52 13.4 (1.-16.8) 31.4.3 35-74 (Age 327 7.4 (6.6-8.2) 95 4.2 (3.4-5.) 43.8.1 35-54 4 4.1 (.2-7.9) 6 3.6 (.8-6.5) 1.8.85 55-64 3 4.4 (.5-9.3) 6 7.2 (1.6-12.8) 62.8.46 65-74 33 19.7 (13.6-25.8) 17 23.3 (13.5-33.2) 18.3.54 35-74 (Age 4 6.8 (4.2-9.5) 29 7.6 (5.-1.1) 1.7.76 35-54 12.4 (.2-.7) 6.2 (.-.4) 55.7.1 55-64 14 2. (.9-3.) 19 2.2 (1.2-3.2) 13.3.72 65-74 127 9.1 (7.6-1.7) 38 6.9 (4.8-9.) 24.7.9 35-74 (Age 153 2.4 (2.-2.8) 63 1.9 (1.4-2.4).4.12 *Data for numbers of subjects and person-years of follow-up are virtually identical to all-cause mortality data, except for the exclusion of 59 subjects (6 with diabetes, 53 without) in cohort 1 and 23 subjects (6 with diabetes, 17 without) in cohort 2 for whom the cause of death could not be ascertained because a death certificate was not obtained. CI indicates confidence interval. 1294 JAMA, April 14, 1999 Vol 281, No. 14 1999 American Medical Association. All rights reserved. P Value Downloaded From: on 11/14/18

Figure 2. Age-Adjusted Mortality Rates for Death Due to,, and for and With and Without in Cohorts 1 and 2, According to Age at Baseline 5 3 4 25 Rate per 1 3 1 15 1 5 Mortality rates are shown per 1 person-years with 95% confidence intervals. Cohort 1 was defined in 1971-1975 and was followed up for mortality through 1982-1984. Cohort 2 was defined in 1982-1984 and was followed up for mortality through 1992-1993. Details about sample sizes, number of deaths, point estimates, and statistical significance are shown in Tables 1 and 2. diabetes in all age groups for all 3 causes of death (P.1). For women without diabetes, differences were statistically significant only at ages 65 to 74 years for all-cause and heart disease mortality (P.5). Among men with diabetes, mortality rates in cohort 1 were generally higher than in cohort 2 at ages 35 to 54 and 55 to 64 years and were slightly lower at ages 65 to 74 years. Among women with diabetes, mortality rates in specific age groups tended to be lower in cohort 1 than in cohort 2. However, 95% confidence limits around the rates of diabetes for both men and women were large, and no differences between cohort 1 and cohort 2 were statistically significant for any cause of death (Table 1 and Table 2). FIGURE 2 shows age-adjusted mortality rates from all causes, heart disease, and ischemic heart disease for men and women with and without diabetes in cohort 1 and cohort 2. For men with and without diabetes, the rate was higher in cohort 1 than in cohort 2 for each cause of death. The differences between cohort 1 and cohort 2 were statistically significant for men without diabetes (P.1) but not for men with diabetes. Among women without diabetes, age-adjusted Figure 3. Percentage Change from Cohort 1 to Cohort 2 in Mortality From,, and for and With and Without Change, % 8 6 4 4 6 8 Data are shown as percentage change in the age-adjusted mortality rates, with 95% confidence intervals. Percentage change was calculated as the mortality rate in cohort 2 minus the rate in cohort 1, divided by the rate in cohort 1, and multiplied by 1. Details about sample sizes, number of deaths, point estimates, and statistical significance are shown in Tables 1 and 2. rates were higher in cohort 1 than in cohort 2, and the difference was statistically significant for all causes (P =.4) and heart disease (P =.9). For women with diabetes, the rate was lower in cohort 1 than in cohort 2 for each cause ofdeath,butnoneofthedifferenceswere statistically significant. FIGURE 3 summarizes the percentage change in age-adjusted mortality rates 1999 American Medical Association. All rights reserved. JAMA, April 14, 1999 Vol 281, No. 14 1295 Downloaded From: on 11/14/18

from cohort 1 to cohort 2. For men without diabetes, there were substantial decreases in the mortality rates for each cause of death, ranging from a 19.7% decline in the all-cause rate to a 43.8% decline in the rate for ischemic heart disease. For men with diabetes, the decreases were smaller and ranged from a 1.1% decline for all causes of death to a 16.6% decline for ischemic heart disease. without diabetes also experienced declines in age-adjusted mortality, including a 12.9% decrease in the allcause rate, a 27.1% decrease in the heart disease rate, and a.4% decrease in the ischemic heart disease rate. In contrast, women with diabetes had increases in their mortality rates that ranged from a 1.7% increase for ischemic heart disease to a 22.9% increase for heart disease. The percentage changes for subjects without diabetes were statistically significant. However, because the 95% confidence intervals for diabetic subjects were wide, the mortality changes for men and women with diabetes did not achieve statistical significance. The mortality data were recomputed using any listing of heart disease or ischemic heart disease on the death certificate. As expected, these multiple-cause mortality rates were higher than those based on heart disease or ischemic heart disease coded only as the underlying cause of death. However, the direction and magnitude of the percentage change from cohort 1 to cohort 2 were similar to those found using the underlying cause alone. The data were also analyzed by retaining, in the components of cohort 1 and cohort 2 without diabetes, those individuals who developed diabetes after the beginning of the mortality observation periods. There was only an approximately 3% increase in the ageadjustedmortalityratesforsubjectswithout diabetes. This change thus had virtually no effect on the results. FIGURE 4 shows the age-adjusted relative risk for mortality (subjects with compared with subjects without diabetes) in cohort 1 and cohort 2. The relative risk was lower in cohort 1 than in cohort 2 for each of the causes of Figure 4. Increases From Cohort 1 to Cohort 2 in the Relative Risk Due to,, and Age-Adjusted Relative Risk 7. 6. 5. 4. 3. 2. 1.. Data are shown as the age-adjusted mortality rate for subjects with diabetes divided by the age-adjusted rate for subjects without diabetes, with 95% confidence intervals. Details about sample sizes, number of deaths, point estimates, and statistical significance are shown in Tables 1 and 2. death in both men and women. The smaller declines in mortality for men with diabetes compared with men without it and the increases in mortality for women with diabetes compared with women without it resulted in increased relative risks for mortality associated with diabetes in cohort 2. COMMENT These data, based on nationally representative samples of adults with and without diabetes, indicate that mortality from all causes, heart disease, and ischemic heart disease appears to have decreased slightly for men with diabetes during the period 1971-1993 and may have increased for women with diabetes. The data also indicate that adults with diabetes experienced less decline in their mortality rates compared with the decline experienced by adults without diabetes during this period. The lower declines for subjects with diabetes occurred for all causes of death, heart disease, and ischemic heart disease. However, confidence limits around the mortality rate changes for subjects with diabetes were large and the magnitude of the changes could not be determined precisely. In contrast, there were large and statistically significant declines in mortality for adults without diabetes, which mirror the changes in the general US population found in other studies. 1-4 The decline in coronary heart disease mortality in the US population has been attributed to improvement in risk factors for heart disease and improvement in medical treatment of patients with heart disease. 15-17 These changes have resulted in decreased incidence of heart disease and increased survival of patients. Based on these studies, there are several possible reasons that smaller mortality declines among adults with diabetes compared with adults without diabetes may have occurred. First, risk factors for mortality, particularly heart disease risk factors, may have decreased less over time in those with diabetes. Second, the incidence of coronary heart disease, including the incidence of recurrent myocardial infarction, may have decreased less in 1296 JAMA, April 14, 1999 Vol 281, No. 14 1999 American Medical Association. All rights reserved. Downloaded From: on 11/14/18

adults with diabetes. Third, patients with diabetes may have benefited less from improved medical treatment of heart disease, and case-fatality rates may have declined less than in patients without diabetes. Although NHANES I and NHEFS do not have data to assess these factors, there are extant cohort studies that include subjects with diabetes that could be investigated. Two other recent studies examined time trends in mortality for people with diabetes. InRochester, Minn, 1-yearsurvival of patients with type 2 diabetes in 197 and 198 relative to survival of the Minnesota white population was studied. 18 Formenwithdiabetes,survivalrelative to men without diabetes was similar for the 197 and 198 cohorts, and the authors concluded that the improved survival experienced by the general Minnesota male population was also experiencedbymenwithdiabetes. Theseresults differfromourfindingsthatmenwithdiabetesinarepresentativesampleoftheus population experienced less reduction in all-cause mortality than men without diabetes. For women with diabetes in Rochester, relative survival was lower for the 198 cohort than the 197 cohort, implyingthatmortalityratesforwomenwith diabetes in Rochester decreased less than theratesforwomenwithoutdiabetes. Our data indicate the same trend. The other study of time trends in diabetes mortality compared ageadjusted mortality rates in the Pima Indians of Arizona in 1975-1982 with rates in 1982-1989. 19 For men, subjects both with and without diabetes experienced small, nonsignificant declines in all-cause mortality; for women, subjects both with and without diabetes experienced small, nonsignificant increases in all-cause mortality. In our study, there may have been differences between the 1971-1975 cohort and the 1982-1984 cohort that we could not measure that may have accounted for the lower declines in mortality for subjects with diabetes compared with subjects without diabetes. In addition, the completeness and accuracy of listing of heart disease and ischemic heart disease on the death certificate may have changed during the 2 cohort periods. However, the fact that the percentage changes from cohort 1 to cohort 2 were similar when multiple causes of death were analyzed indicates that this may not be a major reason for the lower declines in mortality for those with diabetes. Coding of the underlying cause of death was not a factor because the same procedure to select the underlying cause of death was used for all deaths in the study. Our study could not precisely differentiate the types of diabetes, but the adult age of the NHANES I cohort and the high proportion of type 2 diabetes in the US population with diabetes indicate that the results reflect mortality in type 2 patients. Our data also do not permit identification of people with undiagnosed diabetes because neither fasting nor postchallenge glucose samples were obtained. Other studies have shown that mortality rates for individuals with undiagnosed diabetes are approximately equal to the rates for patients with diagnosed diabetes.,21 In summary, this study indicates that mortality rates for all causes, heart disease, and ischemic heart disease in men and women with diabetes have not decreased to the extent that they have for adults without diabetes. Many changes have caused the declines in death rates in the general US population. These changes appear to have been less favorable or less effective for people with diabetes, particularly for women. With the increasing prevalence of diabetes in the United States 22 and the smaller decline in mortality for these individuals, we anticipate that diabetes may become an increasingly important factor for heart disease mortality in the United States. REFERENCES 1. Havlik RJ, Feinleib M, eds. Proceedings of the Conference on the Decline in Coronary Mortality. Washington, DC: US Government Printing Office; 1978. DHEW publication 79-161. 2. Stamler J. The marked decline in coronary heart disease mortality rates in the United States, 1968-91. Cardiology. 1985;72:11-22. 3. Gillum RF. Trends in acute myocardial infarction and coronary heart disease death in the United States. J Am Coll Cardiol. 1994;23:1273-1277. 4. Rosamond WD, Chambless LE, Folsom AR, et al. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med. 1998;13:861-867. 5. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the US population, 1971-1993. Care. 1998;21: 1138-1145. 6. Moss SE, Klein R, Klein BEK. Cause-specific mortality in a population-based study of diabetes. Am J Public Health. 1991;81:1158-1162. 7. Bush TL, Miller SR, Golden AL, Hale WE. Selfreport and medical record report agreement of selected medical conditions in the elderly. Am J Public Health. 1989;79:1554-1556. 8. Harlow SD, Linet MS. Agreement between questionnaire data and medical records. Am J Epidemiol. 1989;129:233-248. 9. Kehoe R, Wu SY, Leske MC, Chylack LT. Comparing self-reported and physician-reported medical history. Am J Epidemiol. 1994;139:813-818. 1. Harris MI, Robbins DC. Prevalence of adultonset IDDM in the US population. Care. 1994; 17:1337-134. 11. Melton LJ, Ochi JW, Palumbo PJ, Chu CP. Sources of disparity in the spectrum of diabetes mellitus at incidence and prevalence. Care. 1983;6:427-431. 12. Chiang CL. Vital Statistics: Special Report 47. Washington, DC: US Government Printing Office; 1961. Report No 9. 13. Kahn HA, Sempos CT. Statistical Methods in Epidemiology. New York, NY: Oxford University Press; 1989:217. 14. Cochran WG. Sampling Techniques. 3rd ed. New York, NY: John Wiley & Sons Inc; 1977:155. 15. Sytkowski PA, Kannel WB, D Agostino RB. Changes in risk factors and the decline in mortality from cardiovascular disease: the Framingham Study. N Engl J Med. 199;322:1635-1641. 16. McGovern PG, Pankow JS, Shahar E, et al. Recent trends in acute coronary heart disease. N Engl J Med. 1996;334:884-89. 17. Hunink MG, Goldman L, Tosteson AN, et al. The recent decline in mortality from coronary heart disease, 198-199: the effect of secular trends in risk factors and treatment. JAMA. 1997;277:535-542. 18. Leibson CL, O Brien PC, Atkinson E, Palumbo PJ, Melton LJ III. Relative contributions of incidence and survival to increasing prevalence of adultonset diabetes mellitus. Am J Epidemiol. 1997;146: 12-22. 19. Sievers ML, Nelson RG, Bennett PH. Sequential trends in overall and cause-specific mortality in diabetic and nondiabetic Pima Indians. Care. 1996;19:17-111.. Jarrett RJ, Shipley MJ. Type 2 (non-insulindependent) diabetes mellitus and cardiovascular disease: putative association via common antecedents. Diabetologia. 1988;31:737-74. 21. Eschwege E, Richard JL, Thibult N, et al. Coronary heart disease mortality in relation with diabetes, blood glucose, and plasma insulin levels. Horm Metab Res. 1985;15(suppl):41-46. 22. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. Care. 1998;21:518-524. 1999 American Medical Association. All rights reserved. JAMA, April 14, 1999 Vol 281, No. 14 1297 Downloaded From: on 11/14/18